Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy
Brief Summary: The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung cancer in comparison to a placebo plus best supportive care (a so-called placebo controlled study).


Options:
A: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cell adenovirus CCL21 vaccine | Intervention Type: BIOLOGICAL; Name: autologous dendritic cell adenovirus CCL21 vaccine; Assigned to Arm(s): Arm 1
C: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)
D: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: A